The world has been locked in a duel with the SARS-CoV-2 virus. The ensuing COVID-19 pandemic has led to previously unthinkable changes, not only to how healthcare systems function, but also the demands placed upon those systems.1,2 From an orthopaedic perspective, elective operations for those suffering with what are often severe, life-limiting conditions were cancelled to allow health services to cope with the successive waves of COVID-19 patients.3 This has resulted in a staggering increase in waiting lists to levels that will take years to bring back under control.4 It has also resulted in twice the number of patients who are waiting for total hip or knee arthroplasty experiencing a state of life which can be considered as “worse than death”.5
In a Rumsfeldian matrix, when emerging from this pandemic, the burden of degenerative joint disease can largely be thought of as our “known knowns”. However, we must not forget that there are also unknown unknowns. COVID-19 has caused repeated anguish to medical services, not only in the management of the disease itself but also in the long-term effects of the virus and its treatment. Chronic symptoms of fatigue, headaches, and dyspnoea are just some of the unexpected consequences which medical professionals have begun to recognize in those who have recovered.6
Other unforeseen consequences may well be found as a result of the drug treatments used to combat the effects of the disease. Glucocorticoids have been used to manage acute respiratory disease syndrome (ARDS) in COVID-19 patients, and have shown to be beneficial in reducing 28-day mortality and the need for mechanical ventilation.7,8 Ostensibly effective in the treatment of ARDS, the widespread use of such treatment may be a double-edged sword.
The detrimental effects of steroids are well documented, and the link between these drugs and the occurrence of femoral head avascular necrosis (AVN) is increasingly recognized.9,10 AVN involves progressive destruction of bone as a result of compromise of bone vasculature,11,12 death of osteocytes and fat cells, and alteration of bone architecture. Following the SARS epidemic in 2003, high rates of femoral head AVN (up to 23%) were noted in patients recovering from the condition who had received steroid treatment.13 The link between COVID-19 and AVN in those who have received steroids has been reported.14 If the rates of AVN reach the heights of those reported following SARS, then orthopaedic services may be subject to a pandemic of AVN, and result in a significant increase in the burden of musculoskeletal disease in the community.
The use of steroid medications and their relationship to AVN have been previously shown to be related to cumulative dose.15 Many COVID-19 patients are started on glucocorticoid medications when they show signs of respiratory deterioration. Dosing of 6 mg dexamethasone daily for ten days was shown by the RECOVERY group to reduce 28-day mortality and the need for mechanical ventilation.8 This dose regime is well below the cumulative dose thresholds described in much of the literature (cumulative dose of 2,000 mg prednisone or its equivalent), but this fact does little to mollify concerns.16,17 AVN has however been described at much lower dose thresholds; furthermore, COVID-19 may independently predispose patients to developing the condition.18,19 Larger steroid doses are commonly used if patients deteriorate or are admitted to critical care, with such patients receiving much higher doses than those used in the RECOVERY trial.20
Many of those affected by AVN of the femoral head are young and active, which makes the management of such a potentially devastating condition troublesome. Treatment options in advanced disease are limited and even though there are a few novel treatments under investigation,21,22 effective joint-preserving treatment relies on early diagnosis. The mainstay of diagnosis is MRI, and it has been shown to be effective in the identification of AVN in asymptomatic high-risk patients. It is not, however, full-proof, with Zhao et al23 showing that there is a significant risk of failing to identify the condition if a single scan conducted two to three months following the insult is relied upon for diagnosis. Despite improvements in joint-preserving procedures, many young patients are managed with arthroplasty surgery, particularly when diagnosed late.24-26
The long-term consequences of the COVID-19 pandemic and its effect on both individuals and wider healthcare systems should be cautiously considered. If the previous experience with SARS and its relationship to subsequent AVN is observed following the current pandemic, then the life-altering effect of AVN on countless individuals will have ramifications for orthopaedic services. An awareness of the possible orthopaedic ramifications of the disease –‘orthopaedic long COVID’ – is therefore vital for all medical professionals dealing with patients convalescing following COVID-19.
1. Magan AA , Plastow R , Haddad FS . Impact of COVID-19 on research . Bone Joint Res . 2020 ; 9 ( 8 ): 531 – 533 . Google Scholar
2. Clement ND , Ng N , Simpson CJ , et al. The prevalence, mortality, and associated risk factors for developing COVID-19 in hip fracture patients: a systematic review and meta-analysis . Bone Joint Res . 2020 ; 9 ( 12 ): 873 – 883 . Google Scholar
3. Jenkins PJ . The early effect of COVID-19 on trauma and elective orthopaedic surgery . British Orthopaedic Association . 2020 . https://www.boa.ac.uk/resources/knowledge-hub/the-early-effect-of-covid-19-on-trauma-and-elective-orthopaedic-surgery.html ( date last accessed 5 January 2021 ). Google Scholar
4. Oussedik S , MacIntyre S , Gray J , McMeekin P , Clement ND , Deehan DJ . Elective orthopaedic cancellations due to the COVID-19 pandemic: where are we now, and where are we heading? Bone Jt Open . 2021 ; 2 ( 2 ): 103 – 110 . Google Scholar
5. Clement ND , Scott CEH , Murray JRD , Howie CR , Deehan DJ , IMPACT-Restart Collaboration . The number of patients “worse than death” while waiting for a hip or knee arthroplasty has nearly doubled during the COVID-19 pandemic . Bone Joint J . 2021 ; 103-B ( 4 ): 672 – 680 . Google Scholar
6. Lopez-Leon S , Wegman-Ostrosky T , Perelman C , et al. More than 50 Long-term effects of COVID-19: a systematic review and meta-analysis . medRxiv . 2021; Preprint . Google Scholar
7. van Paassen J , Vos JS , Hoekstra EM , Neumann KMI , Boot PC , Arbous SM . Corticosteroid use in COVID-19 patients: a systematic review and meta-analysis on clinical outcomes . Crit Care . 2020 ; 24 ( 1 ): 696 . Google Scholar
8. RECOVERY Collaborative Group , Horby P , Lim WS , Emberson JR , et al. Dexamethasone in Hospitalized Patients with Covid-19 . N Engl J Med . 2021 ; 384 ( 8 ): 693 – 704 . Google Scholar
9. Weinstein RS . Glucocorticoid-induced osteonecrosis . Endocrine . 2012 ; 41 ( 2 ): 183 – 190 . Google Scholar
10. Mont MA , Pivec R , Banerjee S , Issa K , Elmallah RK , Jones LC . High-Dose Corticosteroid Use and Risk of Hip Osteonecrosis: Meta-Analysis and Systematic Literature Review . J Arthroplasty . 2015 ; 30 ( 9 ): 1506 – 1512.e5 . Google Scholar
11. Beverly MC , Murray DW . Subchondral physiology and vasculo-mechanical factors in load transmission and osteoarthritis . Bone Joint Res . 2021 ; 10 ( 9 ): 571 – 573 . Google Scholar
12. Addai D , Zarkos J , Pettit M , Sunil Kumar KH , Khanduja V . Outcomes following surgical management of femoroacetabular impingement: a systematic review and meta-analysis of different surgical techniques . Bone Joint Res . 2021 ; 10 ( 9 ): 574 – 590 . Google Scholar
13. Xie L , Liu Y , Fan B , et al. Dynamic changes of serum SARS-coronavirus IgG, pulmonary function and radiography in patients recovering from SARS after hospital discharge . Respir Res . 2005 ; 6 ( 1 ): 5 . Google Scholar
14. Agarwala SR , Vijayvargiya M , Pandey P . Avascular necrosis as a part of ‘long COVID-19’ . BMJ Case Rep . 2021 ; 14 ( 7 ): e242101 . Google Scholar
15. Guo KJ , Zhao FC , Guo Y , Li FL , Zhu L , Zheng W . The influence of age, gender and treatment with steroids on the incidence of osteonecrosis of the femoral head during the management of severe acute respiratory syndrome: a retrospective study . Bone Joint J . 2014 ; 96-B ( 2 ): 259 – 262 . Google Scholar
16. Griffith JF , Antonio GE , Kumta SM , et al. Osteonecrosis of hip and knee in patients with severe acute respiratory syndrome treated with steroids . Radiology . 2005 ; 235 ( 1 ): 168 – 175 . Google Scholar
17. Chan MHM , Chan PKS , Griffith JF , et al. Steroid-induced osteonecrosis in severe acute respiratory syndrome: a retrospective analysis of biochemical markers of bone metabolism and corticosteroid therapy . Pathology . 2006 ; 38 ( 3 ): 229 – 235 . Google Scholar
18. Sodhi N , Acuna A , Etcheson J , et al. Management of osteonecrosis of the femoral head . Bone Joint J . 2020 ; 102-B ( 7_Supple_B ): 122 – 128 . Google Scholar
19. Yildiz N , Ardic F , Deniz S . Very early onset steroid-induced avascular necrosis of the hip and knee in a patient with idiopathic thrombocytopenic purpura . Intern Med . 2008 ; 47 ( 22 ): 1989 – 1992 . Google Scholar
20. López Zúñiga MÁ , Moreno-Moral A , Ocaña-Granados A , et al. High-dose corticosteroid pulse therapy increases the survival rate in COVID-19 patients at risk of hyper-inflammatory response . PLoS One . 2021 ; 16 ( 1 ): e0243964 . Google Scholar
21. Maestro-Paramio L , García-Rey E , Bensiamar F , Saldaña L . Osteoblast function in patients with idiopathic osteonecrosis of the femoral head : implications for a possible novel therapy . Bone Joint Res . 2021 ; 10 ( 9 ): 619 – 628 . Google Scholar
22. Zhu S , Zhang X , Chen X , Wang Y , Li S , Qian W . Comparison of cell therapy and other novel adjunctive therapies combined with core decompression for the treatment of osteonecrosis of the femoral head: a systematic review and meta-analysis of 20 studies . Bone Joint Res . 2021 ; 10 ( 7 ): 445 – 458 . Google Scholar
23. Zhao FC , Hu HX , Zheng X , et al. Clinical analysis of 23 cases of steroid-associated osteonecrosis of the femoral head with normal initial magnetic resonance imaging presentation . Medicine (Baltimore) . 2017 ; 96 ( 49 ): e8834 . Google Scholar
24. Iorio R , Feder O , Schwarzkopf R , Einhorn TA . Outcomes of core decompression and bone marrow aspirate concentrate injection for osteonecrosis of the femoral head . Orthopaedic Proceedings . 2019 ; 101-B ( SUPP_12 ): 46 . Google Scholar
25. Osawa Y , Seki T , Okura T , Takegami Y , Ishiguro N , Hasegawa Y . Long-term outcomes of curved intertrochanteric varus osteotomy combined with bone impaction grafting for non-traumatic osteonecrosis of the femoral head . Bone Joint J . 2021 ; 103-B ( 4 ): 665 – 671 . Google Scholar
26. Sodhi N , Acuna A , Etcheson J , et al. Management of osteonecrosis of the femoral head . Bone Joint J . 2020 ; 102-B ( 7_Supple_B ): 122 – 128 . Google Scholar
G. T. Snowden: Conceptualization, Writing – original draft, Writing – review & editing.
N. D. Clement: Conceptualization, Writing – review & editing.
S. Zhang: Conceptualization, Writing – review & editing.
Q. Xue: Conceptualization, Writing – review & editing.
A. H. R. W. Simpson: Conceptualization, Writing – review & editing.